Verastem Inc to Post FY2017 Earnings of ($1.09) Per Share, Cantor Fitzgerald Forecasts (VSTM)
Verastem Inc (NASDAQ:VSTM) – Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Verastem in a report released on Tuesday. Cantor Fitzgerald analyst M. Goldstein anticipates that the brokerage will post earnings of ($1.09) per share for the year. Cantor Fitzgerald has a “Hold” rating on the stock.
Verastem (NASDAQ:VSTM) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03.
Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating on shares of Verastem in a report on Saturday, November 12th. Zacks Investment Research raised Verastem from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Friday, November 11th.
Verastem (NASDAQ:VSTM) remained flat at $1.20 on Friday. The stock had a trading volume of 50,129 shares. Verastem has a 52 week low of $1.05 and a 52 week high of $1.93. The company’s market capitalization is $44.39 million. The stock has a 50-day moving average of $1.16 and a 200-day moving average of $1.29.
A number of hedge funds and other institutional investors have recently bought and sold shares of VSTM. D. E. Shaw & Co. Inc. raised its position in Verastem by 8.2% in the third quarter. D. E. Shaw & Co. Inc. now owns 572,639 shares of the biopharmaceutical company’s stock worth $762,000 after buying an additional 43,609 shares during the last quarter. Panagora Asset Management Inc. raised its position in Verastem by 3.5% in the third quarter. Panagora Asset Management Inc. now owns 457,577 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 15,612 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Verastem by 9.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 253,675 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 22,600 shares during the last quarter. Emerald Acquisition Ltd. raised its position in Verastem by 4.8% in the third quarter. Emerald Acquisition Ltd. now owns 144,792 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 6,612 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in Verastem during the second quarter worth $179,000.
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.